Darrell H S Tan1,2,3,4, Thomas M Dashwood5, James Wilton6, Abigail Kroch6, Tara Gomes7,8, Diana Martins7. 1. Division of Infectious Diseases, St. Michael's Hospital, Toronto, ON, Canada. Darrell.tan@gmail.com. 2. MAP Centre for Urban Health Solutions, St. Michael's Hospital, 30 Bond St., Toronto, ON, M5B 1W8, Canada. Darrell.tan@gmail.com. 3. Department of Medicine, University of Toronto, Toronto, ON, Canada. Darrell.tan@gmail.com. 4. Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada. Darrell.tan@gmail.com. 5. Department of Medicine, University of Toronto, Toronto, ON, Canada. 6. Ontario HIV Treatment Network, Toronto, ON, Canada. 7. Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada. 8. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
Abstract
OBJECTIVES: HIV pre-exposure prophylaxis (PrEP) is a proven tool for HIV prevention, but PrEP use in Ontario, Canada, and the effects of recent policies are unknown. We estimated the number and characteristics of PrEP users in Ontario and evaluated the impacts of policy changes between July 2015 and June 2018. METHODS: We obtained tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) dispensation data for Ontario from IQVIA, and applied an algorithm to identify use for PrEP. We report prevalent PrEP use for the second quarter of 2018 according to age, sex, region, prescriber specialty, and payer type, and generate "PrEP-to-need ratios" (PNR) by dividing these numbers by the estimated numbers of new HIV diagnoses. We used interventional autoregressive integrated moving average models to examine the impact of three policy changes on PrEP use: Health Canada approval (February 2016), availability of generic TDF/FTC and partial public drug coverage (September 2017), and public drug coverage for individuals aged < 25 years (January 2018). RESULTS: The estimated number of individuals receiving PrEP increased 713%, from 374 in 2015 Q3 to 3041 in 2018 Q2. Among PrEP users in 2018 Q2, 97.5% were male, 60.4% were < 40 years, 67.7% obtained PrEP from a family physician, 77.2% used private insurance, and 67.0% were in Toronto. PNRs were highest in 30-39-year-olds, males, Toronto and the Central East and West regions. Time series analyses found that Health Canada approval (p = 0.0001) and introducing generics/partial public drug coverage (p = 0.002) led to significantly increased use. CONCLUSIONS: PrEP use has risen in Ontario in association with favourable policy changes, but remains far below guideline recommendations.
OBJECTIVES: HIV pre-exposure prophylaxis (PrEP) is a proven tool for HIV prevention, but PrEP use in Ontario, Canada, and the effects of recent policies are unknown. We estimated the number and characteristics of PrEP users in Ontario and evaluated the impacts of policy changes between July 2015 and June 2018. METHODS: We obtained tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) dispensation data for Ontario from IQVIA, and applied an algorithm to identify use for PrEP. We report prevalent PrEP use for the second quarter of 2018 according to age, sex, region, prescriber specialty, and payer type, and generate "PrEP-to-need ratios" (PNR) by dividing these numbers by the estimated numbers of new HIV diagnoses. We used interventional autoregressive integrated moving average models to examine the impact of three policy changes on PrEP use: Health Canada approval (February 2016), availability of generic TDF/FTC and partial public drug coverage (September 2017), and public drug coverage for individuals aged < 25 years (January 2018). RESULTS: The estimated number of individuals receiving PrEP increased 713%, from 374 in 2015 Q3 to 3041 in 2018 Q2. Among PrEP users in 2018 Q2, 97.5% were male, 60.4% were < 40 years, 67.7% obtained PrEP from a family physician, 77.2% used private insurance, and 67.0% were in Toronto. PNRs were highest in 30-39-year-olds, males, Toronto and the Central East and West regions. Time series analyses found that Health Canada approval (p = 0.0001) and introducing generics/partial public drug coverage (p = 0.002) led to significantly increased use. CONCLUSIONS: PrEP use has risen in Ontario in association with favourable policy changes, but remains far below guideline recommendations.
Entities:
Keywords:
HIV; Policy; Pre-exposure prophylaxis; Prevention and control; Public health
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Deborah Yoong; Mark Naccarato; Malika Sharma; James Wilton; Heather Senn; Darrell Hs Tan Journal: Int J STD AIDS Date: 2015-05-29 Impact factor: 1.359
Authors: Darrell H S Tan; Mark W Hull; Deborah Yoong; Cécile Tremblay; Patrick O'Byrne; Réjean Thomas; Julie Kille; Jean-Guy Baril; Joseph Cox; Pierre Giguere; Marianne Harris; Christine Hughes; Paul MacPherson; Shannon O'Donnell; Joss Reimer; Ameeta Singh; Lisa Barrett; Isaac Bogoch; Jody Jollimore; Gilles Lambert; Bertrand Lebouche; Gila Metz; Tim Rogers; Stephen Shafran Journal: CMAJ Date: 2017-11-27 Impact factor: 8.262
Authors: Jean-Michel Molina; Catherine Capitant; Bruno Spire; Gilles Pialoux; Laurent Cotte; Isabelle Charreau; Cecile Tremblay; Jean-Marie Le Gall; Eric Cua; Armelle Pasquet; François Raffi; Claire Pintado; Christian Chidiac; Julie Chas; Pierre Charbonneau; Constance Delaugerre; Marie Suzan-Monti; Benedicte Loze; Julien Fonsart; Gilles Peytavin; Antoine Cheret; Julie Timsit; Gabriel Girard; Nicolas Lorente; Marie Préau; James F Rooney; Mark A Wainberg; David Thompson; Willy Rozenbaum; Veronique Doré; Lucie Marchand; Marie-Christine Simon; Nicolas Etien; Jean-Pierre Aboulker; Laurence Meyer; Jean-François Delfraissy Journal: N Engl J Med Date: 2015-12-01 Impact factor: 91.245
Authors: Qi Guan; Wayne Khuu; Diana Martins; Mina Tadrous; Maria Chiu; Minh T Do; Tara Gomes Journal: Health Promot Chronic Dis Prev Can Date: 2018-06 Impact factor: 3.240
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Patrick S Sullivan; Robertino Mera Giler; Farah Mouhanna; Elizabeth S Pembleton; Jodie L Guest; Jeb Jones; Amanda D Castel; Howa Yeung; Michael Kramer; Scott McCallister; Aaron J Siegler Journal: Ann Epidemiol Date: 2018-06-22 Impact factor: 3.797
Authors: James Wilton; Syed W Noor; Alexandre Schnubb; James Lawless; Trevor A Hart; Troy Grennan; Shawn Fowler; John Maxwell; Darrell H S Tan Journal: BMC Public Health Date: 2018-02-27 Impact factor: 3.295